A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes (PRONTO-T2D)

I8B-MC-ITRN -

The purpose of this study is to compare LY900014 to insulin lispro, both in combination with insulin glargine or insulin degludec, in participants with type 2 diabetes (T2D).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Insulin Degludec, Insulin Glargine, Insulin Lispro, LY900014, Metformin, SGLT2 inhibitor
Could I receive a Placebo?
No
Enrollment Goal
933
Trial Dates
Jul 14, 2017 - Mar 13, 2019
How long will I be in the trial?
Your participation in the main study could last up to 39 weeks. At the end of this period, you may be asked to return for additional follow-up blood tests for up to 26 weeks.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have type 2 diabetes

  • Participants must have been treated with insulin glargine (U100), once daily with or without metformin 3 months

  • Participants must have hemoglobin A1c 7.0% and 10.5%

  • Participants must be of stable weight

  • Participants must have a BMI 23 kilograms per meter squared (kg/m²)

Participants Must Not:

  • Participants must not have type 1 diabetes

  • Participants must not have pancreatitis

  • Participants must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months

  • Participants must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2

  • Participants must not have been taking weight loss drugs, including over-the-counter medications during the last 3 months

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.